Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07217288

Complete Decongestive Therapy Versus Non-pneumatic Compression Therapy in Post Mastectomy Lymphedema

The aim of the study is to compare the effectiveness of Complete Decongestive Therapy and Non-Pneumatic Compression Therapy, both combined with routine physical therapy, in reducing pain and edema volume, improving range of motion, respiratory function, inflammatory markers, and overall quality of life in patients with post-mastectomy lymphedema.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

30 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Post-mastectomy lymphedema (PML) is a chronic, progressive, and disabling complication affecting breast cancer survivors due to disruption of lymphatic drainage following surgery or radiotherapy. It leads to swelling, pain, restricted range of motion, recurrent infections, and reduced quality of life.

Complete Decongestive Therapy (CDT) - a multimodal approach involving manual lymphatic drainage, compression bandaging, skin care, and exercise - is currently the gold standard for lymphedema management. However, CDT is time-consuming, therapist-dependent, and often poorly tolerated or inaccessible for long-term self-management.

Non-Pneumatic Compression Therapy (NPCD) is a newer, portable, and wearable device that provides gradient sequential compression while allowing mobility and daily activity during treatment. It potentially improves adherence, comfort, and patient satisfaction.

Limited comparative research exists evaluating the relative effectiveness of CDT and NPCD in post-mastectomy lymphedema. This study aims to fill this gap and determine which approach produces superior clinical and functional outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females with age between 30 to 60 years. (Monticciolo et al., 2021)
  • Females with unilateral mastectomy post three months of surgery. (Shen et al., 2023) 21
  • A volume difference to the circumferential measurements between the affected and unaffected upper extremities of more volume difference>10%.
  • Completed chemotherapy and/or radiation therapy. (Borman, Yaman, Yasrebi, İnanlı, & Dönmez, 2022)

Exclusion criteria

  • Systemic disorders that might contraindicate the use of sequential compression therapy i.e. chronic kidney disease with renal failure, Congestive heart failure, neurological disorders, respiratory disorders.
  • Presence of active cellulitis, open and partially healed wounds.
  • Patients with lipedema
  • Active or recurrent cancer (defined as < 3 months since completion of cancer therapy)
  • An acute infection within the previous 4 weeks
  • Active venous thromboembolic edema
  • Pregnant women and women who are planning or nursing at study entry.
  • Patients who had participated in any clinical trial of an investigational substance or device during the previous 30 days
  • Potential patients with a cognitive or physical impairment that would interfere with appropriate use of the device. (Rockson, Whitworth, et al., 2022)

Treatment and study plan

Non Pneumatic compression device

Device

Non-Pneumatic Compression Device (NPCD) is a wearable, portable system providing gradient sequential compression through shape-memory alloy actuators instead of air pressure. Frequency: 5 sessions per week for 8 weeks.

Intensity: Moderate, rhythmic static and dynamic compression applied distally to proximally, allowing safe lymphatic drainage.

Time: 40 minutes per session, once daily.

Complete Decongestive Therapy

Other

Complete Decongestive Therapy (CDT), is the gold-standard, non-invasive treatment for lymphedema. It combines manual lymphatic drainage (MLD), compression bandaging, exercise therapy, and skin care to reduce limb swelling and improve lymphatic flow.

Frequency: 5 sessions per week for 8 weeks. Intensity: Gentle manual drainage with multilayer compression Time: 60 minutes per session. Type: Therapist-guided manual and compression therapy followed by self-management.

CDT aims to decongest the limb, prevent fibrosis and infection, and enhance mobility and quality of life in post-mastectomy lymphedema patients.

Primary outcomes

  1. Pain measured by visual analogue scale.

    Time frame: Assessment will be done at baseline, 4th week and 8th week.

    Lymphedema-related symptoms (pain, pressure, heaviness and hardness). The visual analogue scale (VAS) is a validated, subjective measure for acute or chronic pain. Scores are based on self-reported measures of symptoms from 0-10 score. With zero "no pain" and 10 "worst pain". Test-rater reliability has been shown to be good, but higher among literate (r= 0.94, P=0.001) than illetrate patients (r= 0.71, P=0.001).

Secondary outcomes

  1. Edema volume by water displacement method

    Time frame: Assessment will be done at baseline, 4th week and 8th week.

    In the volumetric assessment of lymphedema, the water displacement method involves submerging the affected limb in a water-filled container and measuring the amount of water displaced. The volume change will be determined by subtracting the initial water volume from the final volume after immersing the limb, providing an estimation of limb volume.

  2. Quality of life measured by Lymphoedema Functioning Disability and health questionnaire for the upper limb (Lymph-ICF-UL)

    Time frame: Assessment will be done at baseline, 4th week and 8th week

    Quality of life will be assessed using Lymphoedema Functioning Disability and health questionnaire for the upper limb (Lymph-ICF-UL). The Lymph-ICF-UL consists of 29 questions. The questionnaire consists of 5 domains: the physical function domain contains 7 questions; the mental function domain contains 4 questions; the household domain contains 4 questions; the mobility domain contains 8 questions; and the life/ social life domain contains 6 questions. Each question has to be scored on an 11-point scale (0 to 10). The anchor points for the physical and mental function domain and household domain are 'not at all' and 'a lot'. Those for the mobility and life domain/ social life domain are 'very well' and 'not at all'. The patient has to score his/ her average problems in functioning (i.e. impairments in function and activity limitations and participation restrictions) due to the upper limb lymphoedema.

  3. Functional mobility measured by upper extremity functional index

    Time frame: Assessment will be done baseline, 4th week and 8th week

    The Upper Extremity Functional Index used for measuring the functional mobility of patients with breast related lymphedema. The UEF consists of 20 items, each scored on a 5-point Likert scale ranging from: 0 = Extreme difficulty or unable to perform activity, 1 = Quite a bit of difficulty, 2 = Moderate difficulty, 3 = A little bit of difficulty, 4 = No difficulty. The total score ranges from 0 to 80, with higher scores indicating greater functional ability.

  4. Upper limb range of motion measured by goniometer

    Time frame: Assessment will be done at baseline, after 4th week and 8th week

    The shoulder flexion ROM will be assessed using a 12-inch plastic goniometer. The measurement will be taken with the patient in supine lying with knees flexed, the palm facing medially, and thumbs up. The assessor stood at the side of the affected arm to perform the measurement, with the goniometer axis placed on the middle of the humeral head laterally, the stationary arm parallel with the trunk, and the moveable arm in line with the midline of the humerus. The patient will be instructed to perform flexion (with elevation) of both shoulders to avoid compensatory movement of the affected side. The angle of maximum shoulder flexion measured by the goniometer will be recorded in degrees (°). The intrarater reliability for assessing shoulder flexion ROM using a goniometer has been reported to be excellent (ICC = 0.95, 95% CI = 0.89-0.98)

  5. Respiratory functions measured by spirometer

    Time frame: Assessment will be done baseline, 4th week and 8th week

    Spirometric tests will be used as an objective assessment of respiratory functions. Lung capacity and respiratory muscle strength will be assessed according to the criteria of the American Thoracic Society. During the assessment, participants will be asked to sit with their arms crossed, with clips on their noses. Assessments will be conducted with the filter with in the disposable mouth piece. Evaluation of lung capacity will be started with normal breathing, continued with deep inspirations, and ended with a strong and long expiration from the participant. For the first second, the values of forced expiration volume (FEV1) and forced vital capacity (FVC) will be recorded. The best values will be recorded after repeating the assessments three times. For maximal inspiratory pressure (MIP), the nose of the participant will first closed with a clip; after the forced expiration, maximal inspiration will be recorded.

  6. Inflammatory markers CK, CRP, IL-6, and TNF-α

    Time frame: Assessment will be done at baseline, after 4th week and 8th week

    Venous blood samples will be collected from the non-affected arm by a qualified phlebotomist immediately prior to and after the end of the treatment sessions. Because of risk reduction guidelines (ie, guidelines to minimize injections to the hand and arm), researchers aimed to minimize patient burden by allowing only two blood withdrawals before and after the study. This sampling time point will allow reserachers to determine whether a robust and sustained inflammatory response will be induced by exercises. Samples will be assessed for CK, CRP, IL-6, and TNF-α using standard techniques

Study contacts

Contact information is provided by the study sponsor or research team.

Sahar Fatima, Ph.D

CONTACT

[email protected]

+923371683000

Sponsors and collaborators

Lead sponsor

Lahore University of Biological and Applied Sciences

Other

Collaborators

  • University of Lahore

Registry information

Official study title

Effectiveness of Complete Decongestive-versus Non-pneumattic- Compression Therapy in Patients With Post-mastectomy Lymphedema

Acronym: CDT

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Oct 15, 2025
Registry last updated
Oct 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.